anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In this study, we utilized BBPA, a novel boron amino acid, which replaces the carboxyl group of 4-boronate phenylalanine (BPA) with a boron trifluoride group (-BF3) (-COOH), as a diagnostic molecule for PET imaging of brain tumors, is also a highly efficient boron carrier for BNCT. Preclinical studies suggested \[18F\]BBPA to be a pan-cancer probe that transmembrane transported through large neutral amino acid transporter type-1 (LAT-1). However more studies and evidence are warranted to investigate the clinical value of BBPA PET imaging in human.

This study aim to observe the safety of BBPA, and investigate the diagnostic value of BBPA in the patient with suspected malignant tumors. Patients who meet the eligibility criteria are included in clinical trials after fully communicating the condition, explaining the benefits and risks of clinical trials, clarifying the patient's willingness to include the clinical trial, and signing informed consent. The cohort number, BBPA administrative dose, imaging protocols are decided based on the investigators' preliminary data. The diagnosis and post- examination treatment are based on the recommended guideline, combined with the subject's own situation for standardized diagnosis and treatment
The present invention relates to a method and medicine application thereof for extracting high-purity alpha-Linoleic acid from bunge pricklyash seeds, which provides pure traditional Chinese medicine raw medicine and various preparations for treating cancers, thrombus diseases, hyperlipemia, diabetes mellitus and senile dementia symptom. The raw medicine is extracted from the bunge pricklyash seeds which are traditional Chinese medicinal materials. The preparation of the high-purity alpha-Linoleic acid is divided into the four processes of saponification and acid hydrolysis, subzero refrigeration, urea containing and silver nitrate complexation. The content of the alpha-Linoleic acid in the product goes beyond more than 90%, and achieves the No. 1 class new medicine raw medicine standard of traditional Chinese medicine of China; the various designed preparations have the advantages of standard process, low cost, stable quality and convenient application. The present invention has the efficiency of spleen strengthening, stomach militating, liver nourishing, kidney tonifying, qi circulation promotion, stagnation expelling, blood circulation activation, silt removal, sore removal, pleasure and intelligence benefitting. The present invention can effectively prevent and treat the cancers, the thrombus dieasses, the hyperlipemia, the diabetes mellitus and the senile dementia symptom.
Although highly active antiretroviral therapy (HAART) has been successful in suppressing plasma HIV RNA levels in infected patients, it has not resulted in eradication of virus. It is now clear that virus replication persists despite undetectable plasma viremia in individuals receiving HAART. In this regard, withdrawing HAART, even after prolonged periods of virus suppression, leads to an almost universal rapid rebound of plasma viremia. It is also now clear that prolonged, continuous HAART carries a risk of significant toxicity and side effects. These recent observations may argue for a different approach to HAART with the goals of: 1) durable suppression of virus replication, without an attempt at eradication, and; 2) minimization of toxicity and side effects and improvement in patient life-style. Therefore, we propose to study the virologic and immunologic effects of intermittent versus continuous HAART in HIV-infected individuals as a possible means to achieve these goals. The primary protocol, Cohort 1, will be a randomized controlled study of 45 individuals receiving continuous HAART and 45 individuals receiving intermittent HAART with intervals of one month off therapy followed by two months on therapy. A second cohort of 10 individuals will serve as a pilot study of 2 arms of 5 patients each to evaluate the potential of shorter on-off cycles to maintain suppression of plasma virus and boost HIV-specific immune responses. An extension of Cohort 2 will add 5 patients to the 7 days on/ 7 days off HAART arm with modified exclusion criteria and procedure schedule. Cohort 3 will be a pilot study of 5 individuals who will received 4 days off HAART followed by 3 days on HAART. Cohort 4 will be a pilot study of 8 individuals who will receive a once-daily HAART regimen administered as short cycle intermittent therapy of 7 days off drugs followed by 7 days on drugs. Cohort 5 will be a pilot study of 5 individuals who will receive 3 days off HAART followed by 4 days on HAART. We will analyze CD4+ T-cell counts, viral load, incidence of toxicity and side effects, HIV-specific immune responses and viral resistance to therapy and characterize the virus during rebound plasma viremia.
Post-acute COVID syndrome (PACS) is a global health concern and is often associated with debilitating symptoms. Post-COVID fatigue is a particularly frequent and troubling issue, and its underlying mechanisms remain incompletely understood. One potential contributor is micropathological injury of subcortical and brainstem structures, as has been identified in other patient populations. Texture-based analysis (TA) may be used to measure such changes in anatomical MRI data. The present study develops a methodology of voxel-wise TA mapping in subcortical and brainstem regions, which is then applied to T1-weighted MRI data from a cohort of 48 individuals who had PACS (32 with and 16 without ongoing fatigue symptoms) and 15 controls who had cold and flu-like symptoms but tested negative for COVID-19. Both groups were assessed an average of 4-5 months post-infection. There were no significant differences between PACS and control groups, but significant differences were observed within the PACS groups, between those with and without fatigue symptoms. This included reduced texture energy and increased entropy, along with reduced texture correlation, cluster shade and profile in the putamen, pallidum, thalamus and brainstem. These findings provide new insights into the neurophysiological mechanisms that underlie PACS, with altered tissue texture as a potential biomarker of this debilitating condition.
Children will receive approximately 175 kcal/kg/d of standard ready to use therapeutic food which provides a full daily doses of vitamins and micronutrients. Caregivers will instruct caregivers to feed the supplement only to the enrolled child.
PURPOSE: To obtain a sugarless pectin delivery system which contains each specified amt. of pectin gel component, algin gel component and polymer mesh structure gel component and in which an edible insoluble solid can be added in an enough amt. to improve the release property after molding. CONSTITUTION: This delivery system for sugarless gel candies contains about 1 to 5wt.% pectin gel component, about 0.2 to 1.5wt.% algin gel component, about <=5% polymer mesh structure gel component, and an edible insoluble solid (such as cellulose, fine crystalline cellulose, gum, cereals, seeds, husks and fruits) in an enough amt. to reinforce the inner gel mesh structure so that the structural integration of the gel can be kept when the gel is released from the mold. The polymer mesh structure gel forming agent is preferably gelatin.
Patients will receive the BRAF inhibitor dabrafenib and MEK inhibitor trametinib orally at the RP2D determined in the Phase I/II study (BRF113220): trametinib 2mg QD and dabrafenib 150 mg BID on a continuous basis. A cycle will be defined as 3 weeks in duration. Cycles will be repeated until disease progression (clinical or radiological). Patients may remain on treatment after progression (at the discretion of the investigator) as long as they are still experiencing clinical benefit.
Cyclobenzaprine hydrochloride USP is a skeletal muscle relaxant which relieves muscle spasm of local origin without interfering with muscle function. The active ingredient in cyclobenzaprine hydrochloride extended-release capsules is cyclobenzaprine hydrochloride, USP. Cyclobenzaprine hydrochloride (HCl) is a white, crystalline tricyclic amine salt with the empirical formula C20H21N•HCl and a molecular weight of 311.9. It has a melting point of 217°C, and a pKa of 8.47 at 25°C. It is freely soluble in water and alcohol, sparingly soluble in isopropanol, and insoluble in hydrocarbon solvents. If aqueous solutions are made alkaline, the free base separates. Cyclobenzaprine HCl is designated chemically as 3-(5H-dibenzo[a,d] cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine hydrochloride, and has the following structural formula:

  


  


Cyclobenzaprine hydrochloride extended-release capsules USP for oral administration are supplied in 15 and 30 mg strengths. Cyclobenzaprine hydrochloride extended-release capsules USP contain the following inactive ingredients: sugar spheres, hypromellose, colloidal silicon dioxide, ethyl cellulose. In addition, the capsule shell consists of gelatin, sodium lauryl sulphate, titanium dioxide, FD & C Red 40. Also, 15 mg strength capsules contain FD & C Green 3 and D & C Yellow 10 and 30 mg strength capsules contain FD & C Yellow 6 and FD & C Blue 1. 

USP Dissolution Test pending
Participants who had not received corticosteroid therapy for at least 10 days before starting study drug received ipilimumab,10 mg/kg, as a 90-minute intravenous (IV) infusion every 3 weeks (Weeks 1, 4, 7, and 10) during the Induction Phase. Those eligible (patients who did not discontinue due to toxicity, did not show progression at 24 weeks, and who remained clinically stable) for the Maintenance Phase continued to receive ipilimumab, 10 mg/kg IV, every 12 weeks, beginning at Week 24.
Extracellular vesicles (EVs) have emerged as promising biomaterials for the treatment of different disease. However, only handful types of EVs with clinical transformation potential have been reported to date, and their preparation on a large scale under biosafety-controlled conditions is limited. In this study, we characterize a novel type of EV with promising clinical application potential: dehydration-induced extracellular vesicles (DIMVs). DIMV is a type of micron-diameter cell vesicle that contains more bioactive molecules, such as proteins and RNA, but not DNA, than previously reported cell vesicles. The preparation of DIMV is extraordinarily straightforward, which possesses a high level of biosafety, and the protein utilization ratio is roughly 600 times greater than that of naturally secreted EVs. Additional experiments demonstrate the viability of pre- or post-isolation DIMV modification, including gene editing, nucleic acid encapsulation or surface anchoring, size adjustment. Finally, on animal models, we directly show the biosafety and immunogenicity of DIMV, and investigate its potential application as tumour vaccine or drug carrier in cancer treatment.
Risk Summary   
Small amounts of contraceptive steroids and/or metabolites, including etonogestrel and ethinyl estradiol are transferred to human milk. Harmful effects have not been observed in breastfed infants exposed to CHCs through breast milk. CHCs can reduce milk production in breastfeeding mothers. This is less likely to occur once breastfeeding is well-established; however, it can occur at any time in some women. 

When possible, advise the nursing mother to use non-estrogen-containing contraception until she has completely weaned her child. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for EnilloRing and any potential adverse effects on the breastfed child from EnilloRing or from the underlying maternal condition.
The study - interventional, nonpharmacological, using medical devices, nonprofit - is aimed at evaluating the potential effectiveness of a multimodal intervention for the treatment of unipolar depression. The intervention involves the use of a neuro-stimulation technique, the Transcranial Direct Current Stimulation (transcranial Direct Current Stimulation - tDCS), combined with a psychotherapy intervention, metacognitive therapy (MetaCognitive Therapy, MCT). TDCS is a noninvasive neurostimulation technique involving the transcranial application of a low-amperage electric current at a region of the cerebral cortex involved in the pathogenesis of major depression, the dorsolateral prefrontal cortex. It has been demonstrated how such stimulation has a neuromodulating effect on synaptic plasticity, with efficacy in unipolar major depression. The technique also has a good safety, as it is not associated with major side effects. MCT is based on the metacognitive model, according to which psychopathological processes are consequent to a cognitive style characterized by repetitive forms of thinking (such as rumination) and maladaptive behaviors such as avoidance and thought suppression. The MCT, through attention training techniques, detached mindfulness and behavioral interventions on metacognitions, has shown effectiveness in major depressive disorder comparable to that of psychotherapeutic interventions considered, within psychotherapies, to be first-line such as cognitive-behavioral therapy. The experimental design will be that of a randomized, double-blind study with three arms of treatment, each consisting of 8 sessions, involving the administration of 1) the neurostimulation intervention (tDCS), 2) of the psychotherapeutic intervention alone (MCT), 3) of both techniques in consecution (tDCS-MCT). This design is aimed at evaluating a potential additive/synergistic effect of the two interventions when combined. During the tDCS sessions, each lasting 20 minutes, the patient will apply the technique of attention training, aimed at further activating the region stimulated by neurostimulation, so as to so as to amplify the plasticity stimulated by tDCS, achieving a synergistic effect. To follow, a 40-minute MCT session will be carried out. The effectiveness of these interventions will be assessed by heteroadministered and self-administered at time zero, after treatment, at two follow-ups of 6 and 12 months. Before and after the treatment cycle (tDCS sessions and MCT sessions), a subgroup of patients will be explored, in the context of a pilot study, the TMS-EEG correlates of the change in symptomatology depression, which can be correlated with the different proposed therapeutic interventions.
Motor training results in use dependent plasticity (UDP), thought to underlie recovery of motor function after brain injury. The purpose of this protocol is to determine (a) if movement observation results in encoding of a motor memory in the primary motor cortex and (b) if observation of motor training can enhance the effects of physical training in healthy volunteers. If so, this may become an important tool in rehabilitative treatment for patients who are unable or partially able to train. We will test our hypotheses by means of focal single pulse transcranial magnetic stimulation (TMS) in a group of healthy volunteers. Our outcome measure will be the change in TMS-evoked movement direction as a function of training strategy. So far we found that this is the case in healthy volunteers (see data in analysis of the study). The purpose of this protocol is to determine if action observation can elicit the same effects in adult chronic ischemic stroke patients who have had originally significant motor weakness but recovered to the point of being able to perform the motor tasks, possibly resulting in a useful rehabilitative strategy.
We used the "Aging Wisely" program for seniors living in the community, which uses elements of CBT and is specifically designed for older people over the age of 65 living in the community who may be in a worried, anxious or depressed mood. The program focuses on psychoeducation to manage these feelings. Seniors learn to change the ways they think and behave that maintain depression and anxiety. The sessions include education on the process of aging, coping with loneliness, improving sleep, coping with worry and avoidance, coping with loss and death. During the sessions, participants learn to track mood, motivation to change, goal setting, planning pleasant activities, identifying thoughts, working with useless thoughts, and practice techniques to replace useless thoughts. The last two sessions are dedicated to assertiveness and communication, and preventing recurrence of problems.
Expansion Cohort B (ECB): Approximately 20 participants will be enrolled and treated with atezolizumab + vemurafenib + cobimetinib. Serial biopsy tissue sample collections of accessible lesions will be mandatory for all participants. The doses will be decided based on the results of Cohorts 1-4.
PROBLEM TO BE SOLVED: To attain an ultrasonic imaging without irradiating an examinee with ultrasonic wave by thermally stimulating and destroying a micro-balloon injected to the examinee and forming the image based on ultrasonic wave which is generated at that time. SOLUTION: An operator positions an ultrasonic probe 52 and an electromagnetic irradiator 522 at desired positions of the examinee 54, operates an operating part 520 and starts photographing an image. Thus, image picking-up is executed under control by a control part 518. The part 518 controls a driving part 524 and permits the equipment 522 to generate electromagnetic wave. The wave heats the examinee 54, each micro-balloon in a micro-balloon imaging agent 540 is thermally expanded by temp. increase owing to it and destroyed and they respectively generate ultrasonic wave. The wave generated by each balloon reaches the two-dimensional array of the probe 52 as spherical wave and propagates on the surface of the array while drawing a concentric circle by its wave surface.
Arm1:preoperative Toripalimab with chemoradiotherapy group Participants will receive carboplatin (AUC=2) VD 30min and paclitaxel liposome (50mg/m²) CIV 24h on day 3,10,17,24,31. And radiotherapy will start from day 1 to 31 of chemotherapy. A total of 41.4 Gy, 23 fractions of 1.8 Gy. Participants will also receive Toripalimab(240mg) VD 30 min on days 3, 24 and 45. After the above neoadjuvant therapy is over, the short-term efficacy evaluation will be performed first, and then a scheduled radical radical resection will be performed from days 59 to 73.
Everyone in the study will get Mindfulness Coach and an orientation session. Mindfulness Coach is a self-guided mHealth intervention designed to help individuals learn MT, an evidence-based treatment to enhance health, wellness and mental health. The intervention will be introduced during 1 in-person session by a trained research assistant with 1-2 booster instructional phone call at 7 and 14-days to ensure that the participant knows how and is encouraged to use the app. The participant will also be provided with a laminated card that provides the basic instructions. We will encourage the participant to use Mindfulness Coach weekly for 8 weeks, or more if desired, as this treatment dose is commensurate with most in-person MT psychotherapy treatment protocols.
The invention relates to the technical field of development and application of antitumor drugs, in particular to application of enhanced protein in a product for treating gastric cancer and the product for treating gastric cancer, wherein the product comprises the following components: the enhanced protein can increase the sensitivity of gastric cancer to platinum drugs. The enhanced protein is at least one of IFIT1, YBX1 and SFPQ. Through experimental study, it is found that: patients with high IFIT1 expression are more sensitive to platinum drugs. Drug sensitivity experiments on cell level by over-expressing IFIT1 and knocking down MNK45 cell lines also prove that the over-expression of IFIT1 promotes the sensitivity of platinum drugs. IFIT1 can promote proliferation, invasion and metastasis of gastric cancer cells. It was confirmed by scratch experiments that YBX and SFPQ also promote migration of gastric cancer cells. Meanwhile, YBX1 and SFPQ in gastric cancer are found to be involved in the regulation of the sensitivity of IFIT1 to platinum drugs.
Described are general means and methods of diagnosing and treating the phenotypic spectrum as well as the overlapping clinical characteristics with several forms of inherited abnormal expression and/or function of the CYP2B6 genes. In particular, polynucleotides of molecular variant CYP2B6 genes which, for example, are associated with insufficient metabolization and/or sensitively of drugs, and vectors comprising such polynucleotides are provided. Furthermore, host cells comprising such polynucleotides or vectors and their use for the production of variant CYP2B6 proteins are described. In addition, variant CYP2B6 proteins and antibodies specifically recognizing such proteins as well as transgenic non-human animals comprising the above-described polynucleotide or vectors are provided. Described are also methods for identifying and obtaining inhibitors for therapy of disorders related to the malfunction of the CYP2B6 gene as well as methods of diagnosing the status of such disorders. Pharmaceutical and diagnostic compositions useful for diagnosing and treating various diseases with drugs that are substrates, inhibitors or modulators of the CYP2B6 gene product are described as well.
Participants assigned to the "Web-based prescription opioid prevention for adolescents" will immediately (post-group assignment) be asked to start completing modules. All youth can choose to access modules in any order. Youth will be encouraged to complete 1-2 modules per login, 2x/week (about 30 mins. minimum per login to parallel the manner in which other evidence-based prevention programs have been provided to youth. We do not plan to place an artificial constraint on module access but will encourage youth to use the flexible, web- based tool in a manner that is most useful to them. In our experience providing online interventions, we expect that most youth will complete all 9 modules within 3-4 weeks.
The invention discloses a Chinese isolate of Leachiii mycoplasma, an isolation medium and purpose thereof. The Chinese isolate of Leachiii mycoplasma has a microbe preservation No. of CGMCC No.3808. The invention also discloses a medium suitable for isolation or subculturing of the Chinese isolate of Leachiii mycoplasma. Pathogenic test results show that inoculating subculture of Leachiii mycoplasma isolate of the invention in joint of 1-2 month healthy calf can replicate typical polyarthritis and cause certain death; the dead calf has obvious constitutional symptom and obvious pathological changes in multiple tissues and organs. According to clinical symptoms and pathological changes of clinical morbidity and artificial inoculated calf, epidemic features of the disease, tracking epidemiology investigation and singular PRC identification and genetic evolution analysis of isolated pathogeny, it is proved that the mycoplasma isolated by the invention is Leachiii mycoplasma.
PURPOSE:To obtain the subject device having a skin-adhering layer having high releasability and quick transcutaneous absorbability without lowering the shape-retainability even in the presence of ethanol, etc., by including ethanol and/or a drug into an ethylene-vinyl acetate copolymer. CONSTITUTION:The objective transcutaneous absorption device has a skin- adhering layer produced by including ethanol and/or a drug into an ethylene vinyl acetate copolymer. When the transcutaneous absorbability of the drug is not improved by the use of ethanol, an absorbefacient (e.g. hexanol, nicotinic acid or limonene) is added to the skin-adhering layer in an amount of <=50wt.%. The ethylene-vinyl acetate copolymer preferably contains 30-50wt.% of vinyl acetate unit. The content of ethanol is preferably 0.0001-50wt.% in the skin- adhering layer. The concentration of the drug in the adhering layer is preferably 0.001-50wt.%.